Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Exp Dermatol ; 2024 May 23.
Article in English | MEDLINE | ID: mdl-38778741
2.
Breast ; 70: 82-91, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37419078

ABSTRACT

BACKGROUND: Recent clinical evidence showed that breast cancer with low HER2 expression levels responded to trastuzumab deruxtecan therapy. The HER2-low cancers comprise immunohistochemistry (IHC) score 1+ and 2+ ISH non-amplified tumours, currently classified as HER2 negative. Little data exists on the reproducibility of pathologists reporting of HER2-low cancer. PATIENT AND METHODS: Sixteen expert pathologists of the UK National Coordinating Committee for Breast Pathology scored 50 digitally scanned HER2 IHC slides. The overall level of agreement, Fleiss multiple-rater kappa statistics and Cohen's Kappa were calculated. Cases with low concordance were re-scored by the same pathologists after a washout period. RESULTS: Absolute agreement was achieved in 6% of cases, all of which scored 3+. Poor agreement was found in 5/50 (10%) of cases. This was due to heterogeneous HER2 expression, cytoplasmic staining and low expression spanning the 10% cut-off value. Highest concordance (86%) was achieved when scores were clustered as 0 versus others. Improvement in kappa of overall agreement was achieved when scores 1+ and 2+ were combined. Inter-observer agreement was moderate to substantial in the whole cohort but fair to moderate in the HER2-low group. Similarly, consensus-observer agreement was substantial to almost perfect in the whole cohort and moderate to substantial in the HER2-low group. CONCLUSION: HER2-low breast cancer suffers from lower concordance among expert pathologists. While most cases can reproducibly be classified, a small proportion (10%) remained challenging. Refining the criteria for reporting and consensus scoring will help select appropriate patients for targeted therapy.


Subject(s)
Breast Neoplasms , Humans , Female , Breast Neoplasms/pathology , Pathologists , Receptor, ErbB-2/metabolism , Reproducibility of Results , Ireland , Biomarkers, Tumor , Observer Variation
3.
J Clin Pathol ; 76(4): 234-238, 2023 Apr.
Article in English | MEDLINE | ID: mdl-34620607

ABSTRACT

AIMS: There is little information on the impact of COVID-19 on breast pathologists. This survey assessed the effect of the COVID-19 pandemic on UK and Ireland-based breast pathologists to optimise working environments and ensure preparedness for potential future pandemics. METHODS: A 35-question survey during the first wave of COVID-19 infections in the UK including questions on workload, working practices, professional development, training, health and safety and well-being was distributed to consultant breast pathologists and responses collected anonymously. RESULTS: There were 135 responses from breast pathologists based in the UK and Ireland. Most participants (75.6%) stated that their workload had decreased and their productivity dropped. 86/135 (63.7%) were given the option of working from home and 36% of those who did reported improved efficiency. Multidisciplinary team meetings largely moved to virtual platforms (77.8%) with fewer members present (41.5%). Online education, including webinars and courses, was utilised by 92.6%. 16.3% of pathologists reported shortages of masks, visors or gowns as the the most common health and safety concern. COVID-19 had a significant negative impact on the physical and mental health of 33.3% of respondents. A small number of pathologists (10.4%) were redeployed and/or retrained. CONCLUSION: The UK and Ireland breast pathologists adapted to the rapid change and maintained service delivery despite the significant impact of the pandemic on their working practices and mental health. It is important to apply flexible working patterns and environments that improve productivity and well-being. The changes suggested should be considered for long-term shaping of breast pathology services.


Subject(s)
COVID-19 , Humans , COVID-19/epidemiology , Pathologists , Ireland/epidemiology , Pandemics , Surveys and Questionnaires , United Kingdom/epidemiology
4.
BMJ Case Rep ; 20182018 Jan 03.
Article in English | MEDLINE | ID: mdl-29298788

ABSTRACT

Granulomatosis with polyangiitis (GPA) causing liver injury is rare. Where liver biopsies have been taken findings are not always typical and diagnosis can be challenging. Here, we present a case of a 58-year-old male who on admission to hospital was found to have acute liver injury. Diagnosis of liver involvement in GPA is supported by liver histology and the resolution of hepatitis after commencement of immunosuppressive treatment.


Subject(s)
Granulomatosis with Polyangiitis/complications , Granulomatosis with Polyangiitis/pathology , Liver Diseases/drug therapy , Liver Diseases/pathology , Liver/injuries , Acute Disease/epidemiology , Granulomatosis with Polyangiitis/diagnosis , Humans , Immunologic Factors/therapeutic use , Liver/pathology , Liver Diseases/etiology , Liver Function Tests/methods , Male , Middle Aged , Rare Diseases , Rituximab/administration & dosage , Rituximab/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...